Akebia Therapeutics, Inc.
AKBA · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $236M | $160M | +47.5% |
| Operating income | $23.5M | −$50.5M | |
| Net income | −$5.34M | −$69.4M | +92.3% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $36.9M | $58.8M | −37.2% |
| Operating income | −$11.5M | $4.40M | |
| Net income | −$14.4M | $500K |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Akebia's revenue in FY2025?
- $236M in FY2025 (Fiscal year ended Dec 31, 2025), +47.5% vs $160M a year earlier, per its 10-K filed Feb 2026.
- Was Akebia profitable in FY2025?
- No: net income was −$5.34M and operating income $23.5M in FY2025.
- What was Akebia's revenue in Q3 2026?
- $36.9M (−37.2% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.